Healx Initiates Phase II Trial for AI-Discovered Rare Disease Candidate with $47M Funding

Company and Funding:
Healx has secured $47 million in funding to advance its lead candidate, HLX-1502, into a Phase II clinical trial.

Disease Target:
The candidate, HLX-1502, is designed to treat neurofibromatosis Type 1 (NF1), a rare genetic disorder.

AI Technology:
The drug was developed using artificial intelligence (AI) to identify potential therapeutic targets.

Trial Timeline:
Healx plans to initiate the Phase II trial by the end of the year.

Investment Details:
The $47 million investment is part of Healx's Series C funding round, supporting the progression of HLX-1502 into clinical trials.